Korean Multiple Myeloma Working Party Report issue

Academic/Hospital Phase 2
Founded: Korea, Republic of (2005)

Organization Overview

First Clinical Trial
2005
NCT00319865
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2006

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (4)

bortezomib (velcade) (3 trials)

doxorubicin (Doxil) (1 trial)

thalidomide (Thalomid) (2 trials)

urea (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Multiple Myeloma (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 4